PMID- 32897516
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20210708
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 71
IP  - 1
DP  - 2021 Jan
TI  - Inhibition of the RANKL with denosumab has no effect on circulating markers of 
      atherosclerosis in women with postmenopausal osteoporosis: a pilot study.
PG  - 199-207
LID - 10.1007/s12020-020-02483-2 [doi]
AB  - PURPOSE: We evaluated the early effect of denosumab on circulating markers of 
      atherosclerosis in women with postmenopausal osteoporosis. METHODS: Denosumab 
      (60 mg) was administered subcutaneously every 6 months (m) in 27 women (mean age 
      75 +/- 5 years) with postmenopausal osteoporosis and high cardiovascular risk for a 
      total of 24 m. Zoledronic acid was administered in 6 age-matched women as a 
      single intravenous dose. Serum levels of vascular cell adhesion protein 1 
      (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E and P selectin, CD-40 
      ligand (CD40L), interleukin-6 (IL-6), matrix metalloproteinase (MMP) 1 and 9, 
      monocyte chemoattractant protein-1 (MCP-1), fibrinogen (FBG), and high 
      sensitivity C-reactive protein (hs-CRP) were measured at baseline, 15 days (d), 
      2, 6 and 12 m after dosing. In the denosumab group, observation was extended to 
      24 m as secondary endpoint. RESULTS: Serum ICAM-1 levels showed significant 
      increase in the zoledronic acid group (+18 +/- 0.1%; p < 0.01) at 12 m. In the 
      denosumab group, we observed a significant increase in serum CD40L (+2 +/- 0.8%; 
      p < 0.001), MMP-1 (+11 +/- 0.4%, p < 0.02), and MMP-9 (+39.4 +/- 0.8%, p < 0.01) at 
      24 m. There was a significant increase in serum FBG and hs-CRP in both groups at 
      12 m (denosumab:+2.2 +/- 0.2% and +50.3 +/- 1.6%; zoledronic acid: +9.4 +/- 0.1 and 
      +81.8 +/- 0.8%; p < 0.01). No significant between-group differences were found. 
      CONCLUSIONS: 24-m treatment with denosumab has no effect on the circulating 
      markers of atherosclerosis in women with postmenopausal osteoporosis. Fluctuation 
      of serum ICAM-1, CD40L, MMPs, FBG and hs-CRP can be ascribed to perturbation of 
      immunological mechanisms stimulated by denosumab and zoledronic acid.
FAU - Cipriani, Cristiana
AU  - Cipriani C
AUID- ORCID: 0000-0002-0141-1202
AD  - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 
      Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. 
      cristiana.cipriani@gmail.com.
FAU - Piemonte, Sara
AU  - Piemonte S
AD  - ASL ROMA 1, Distretto 2, via Tagliamento 19, 00198, Rome, Italy.
FAU - Colangelo, Luciano
AU  - Colangelo L
AD  - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 
      Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
FAU - De Martino, Viviana
AU  - De Martino V
AD  - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 
      Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
FAU - Diacinti, Daniele
AU  - Diacinti D
AD  - Department of Radiological Sciences, Oncology and Pathology, Sapienza University 
      of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
FAU - Ferrone, Federica
AU  - Ferrone F
AD  - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 
      Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
FAU - Piazzolla, Valentina
AU  - Piazzolla V
AD  - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 
      Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
FAU - Fassino, Valeria
AU  - Fassino V
AD  - Department of Experimental Medicine, Sapienza University of Rome, Viale Regina 
      Elena 324, 00161, Rome, Italy.
FAU - Nieddu, Luciano
AU  - Nieddu L
AD  - Faculty of Economics, UNINT University, Via Cristoforo Colombo 200, 00147, Rome, 
      Italy.
FAU - Minisola, Salvatore
AU  - Minisola S
AD  - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 
      Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
FAU - Pepe, Jessica
AU  - Pepe J
AD  - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 
      Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Bone Density Conservation Agents)
RN  - 4EQZ6YO2HI (Denosumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Atherosclerosis/drug therapy
MH  - Bone Density
MH  - *Bone Density Conservation Agents/therapeutic use
MH  - Denosumab/therapeutic use
MH  - Female
MH  - Humans
MH  - *Osteoporosis, Postmenopausal/drug therapy
MH  - Pilot Projects
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Cardiovascular
OT  - Denosumab
OT  - Osteoporosis
OT  - Postmenopausal
EDAT- 2020/09/09 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/09/08 12:16
PHST- 2020/05/28 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/09 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/09/08 12:16 [entrez]
AID - 10.1007/s12020-020-02483-2 [pii]
AID - 10.1007/s12020-020-02483-2 [doi]
PST - ppublish
SO  - Endocrine. 2021 Jan;71(1):199-207. doi: 10.1007/s12020-020-02483-2. Epub 2020 Sep 
      8.